Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

29.35

Margin Of Safety %

Put/Call OI Ratio

0.31

EPS Next Q Diff

0.01

EPS Last/This Y

1.14

EPS This/Next Y

0.26

Price

10.51

Target Price

31.92

Analyst Recom

1.64

Performance Q

11.21

Relative Volume

0.62

Beta

2.29

Ticker: NTLA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25NTLA13.60.330.2165585
2025-07-28NTLA13.110.320.5666508
2025-07-29NTLA12.510.330.1867289
2025-07-30NTLA12.310.330.7267495
2025-07-31NTLA11.640.320.4267897
2025-08-01NTLA11.480.320.7172375
2025-08-04NTLA12.120.314.2572449
2025-08-05NTLA11.560.320.9573779
2025-08-06NTLA11.380.320.8974002
2025-08-07NTLA11.460.321.0474190
2025-08-08NTLA10.80.310.3674949
2025-08-11NTLA10.750.310.1475110
2025-08-12NTLA10.860.300.2874444
2025-08-13NTLA10.920.280.2173771
2025-08-14NTLA10.90.260.3072690
2025-08-15NTLA10.990.250.3272664
2025-08-18NTLA10.730.270.0654821
2025-08-19NTLA10.30.261.4055443
2025-08-20NTLA10.20.290.6557090
2025-08-21NTLA10.130.310.1658290
2025-08-22NTLA10.520.310.2358660
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25NTLA13.6033.7-28.1-4.14
2025-07-28NTLA13.1133.744.1-4.14
2025-07-29NTLA12.5033.752.8-4.14
2025-07-30NTLA12.3333.728.3-4.14
2025-07-31NTLA11.6433.760.2-4.14
2025-08-01NTLA11.4933.728.6-4.14
2025-08-04NTLA12.1233.7-24.7-4.14
2025-08-05NTLA11.5833.752.8-4.14
2025-08-06NTLA11.3833.931.9-4.16
2025-08-07NTLA11.4633.912.6-4.16
2025-08-08NTLA10.7926.664.1-4.16
2025-08-11NTLA10.7526.6-7.5-4.16
2025-08-12NTLA10.8626.2-18.3-4.16
2025-08-13NTLA11.0026.2-19.7-4.16
2025-08-14NTLA10.9026.5-2.8-4.16
2025-08-15NTLA10.9926.5-16.6-4.11
2025-08-18NTLA10.7225.88.4-4.11
2025-08-19NTLA10.2925.821.1-4.11
2025-08-20NTLA10.2025.8-3.7-4.11
2025-08-21NTLA10.1225.8-4.0-4.11
2025-08-22NTLA10.5125.8-39.4-4.11
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25NTLA-0.292.3429.63
2025-07-28NTLA-0.292.0229.63
2025-07-29NTLA-0.292.0229.63
2025-07-30NTLA-0.292.0229.63
2025-07-31NTLA-0.292.0229.63
2025-08-01NTLA-0.292.0229.63
2025-08-04NTLA-0.291.5029.63
2025-08-05NTLA-0.291.5029.63
2025-08-06NTLA-0.291.5029.63
2025-08-07NTLA-0.291.5029.63
2025-08-08NTLA-0.291.5029.63
2025-08-11NTLA-0.280.9328.59
2025-08-12NTLA-0.280.9329.42
2025-08-13NTLA-0.280.9329.42
2025-08-14NTLA-0.280.9329.42
2025-08-15NTLA-0.280.9329.42
2025-08-18NTLA-0.29-1.0229.35
2025-08-19NTLA-0.29-1.0229.35
2025-08-20NTLA-0.29-1.0229.35
2025-08-21NTLA-0.29-1.0229.35
2025-08-22NTLA1.36-1.0229.35
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.99

Avg. EPS Est. Current Quarter

-0.99

Avg. EPS Est. Next Quarter

-0.98

Insider Transactions

1.36

Institutional Transactions

-1.02

Beta

2.29

Average Sales Estimate Current Quarter

13

Average Sales Estimate Next Quarter

18

Fair Value

Quality Score

16

Growth Score

31

Sentiment Score

10

Actual DrawDown %

94.8

Max Drawdown 5-Year %

-96.4

Target Price

31.92

P/E

Forward P/E

PEG

P/S

21.36

P/B

1.55

P/Free Cash Flow

EPS

-4.69

Average EPS Est. Cur. Y​

-4.11

EPS Next Y. (Est.)

-3.85

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-908.48

Relative Volume

0.62

Return on Equity vs Sector %

-91.8

Return on Equity vs Industry %

-78.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

0.04

EBIT Estimation

-39.4
Intellia Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 403
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
stock quote shares NTLA – Intellia Therapeutics, Inc. Stock Price stock today
news today NTLA – Intellia Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NTLA – Intellia Therapeutics, Inc. yahoo finance google finance
stock history NTLA – Intellia Therapeutics, Inc. invest stock market
stock prices NTLA premarket after hours
ticker NTLA fair value insiders trading